Guest guest Posted September 17, 2004 Report Share Posted September 17, 2004 Ah well there's plenty of holes in this head too.....just ask my family! B > > >This is all I can offer off the top of my head. > >Barbara > > > > > > > > > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 17, 2004 Report Share Posted September 17, 2004 Ah well there's plenty of holes in this head too.....just ask my family! B > > >This is all I can offer off the top of my head. > >Barbara > > > > > > > > > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 , that was funny, but true in the fact that she is one sharp cookie... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 , that was funny, but true in the fact that she is one sharp cookie... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 , that was funny, but true in the fact that she is one sharp cookie... Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, wheatchild@... writes: Dr. Korson said that complex I defects are often associated with fatty acid oxidation impairment. He says the approach to management may not change much if the FAO is confirmed, but it might help point toward changes in vitamin or cofactor therapy. Hi Barbara, Thank you so much for all your info! I agree that you have a wealth to share with others. Thanks for telling me about the chat transcript...Dr Korson is the mito doc that I am seeing on Thursday so I am sure he will have things to add. Did they actually identify the type of FOD that you have? From what I understand, sometimes they just know there is something abnormal going on in the beta oxidation cycle but can't always identify the actual genetic name of it....I guess it's similar to mito in that way! And....does anyone know how they figure out if the FOD is primary or secondary? I almost always hear it is secondary, but don't really understand how they figure that out. Thanks again for your help! Malisa Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, wheatchild@... writes: Dr. Korson said that complex I defects are often associated with fatty acid oxidation impairment. He says the approach to management may not change much if the FAO is confirmed, but it might help point toward changes in vitamin or cofactor therapy. Hi Barbara, Thank you so much for all your info! I agree that you have a wealth to share with others. Thanks for telling me about the chat transcript...Dr Korson is the mito doc that I am seeing on Thursday so I am sure he will have things to add. Did they actually identify the type of FOD that you have? From what I understand, sometimes they just know there is something abnormal going on in the beta oxidation cycle but can't always identify the actual genetic name of it....I guess it's similar to mito in that way! And....does anyone know how they figure out if the FOD is primary or secondary? I almost always hear it is secondary, but don't really understand how they figure that out. Thanks again for your help! Malisa Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, wheatchild@... writes: Dr. Korson said that complex I defects are often associated with fatty acid oxidation impairment. He says the approach to management may not change much if the FAO is confirmed, but it might help point toward changes in vitamin or cofactor therapy. Hi Barbara, Thank you so much for all your info! I agree that you have a wealth to share with others. Thanks for telling me about the chat transcript...Dr Korson is the mito doc that I am seeing on Thursday so I am sure he will have things to add. Did they actually identify the type of FOD that you have? From what I understand, sometimes they just know there is something abnormal going on in the beta oxidation cycle but can't always identify the actual genetic name of it....I guess it's similar to mito in that way! And....does anyone know how they figure out if the FOD is primary or secondary? I almost always hear it is secondary, but don't really understand how they figure that out. Thanks again for your help! Malisa Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, wheatchild@... writes: My understanding is that secondary defects are probably present from the start due to biochemical " domino effects. " I missed this sentence....maybe that's why they say FOD's are secondary to mito? If something isn't working in the electron transport chain then maybe it backs up into the beta oxidation cycle??? Malisa Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, wheatchild@... writes: My understanding is that secondary defects are probably present from the start due to biochemical " domino effects. " I missed this sentence....maybe that's why they say FOD's are secondary to mito? If something isn't working in the electron transport chain then maybe it backs up into the beta oxidation cycle??? Malisa Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > My understanding is that secondary defects are probably > present from the start due to biochemical " domino effects. " > > > > > I missed this sentence....maybe that's why they say FOD's are secondary to > mito? If something isn't working in the electron transport chain then maybe it > backs up into the beta oxidation cycle??? More or less. When one cycle is out of balance, it may throw other cycles off kilter. Below I will paste the abstract I posted for about secondary beta ox problems in a child with a primary defect in the electron transport chain. In that case, the authors felt the biochemical evidence clearly indicated that the abnormalities in beta ox were secondary. Butyrylcarnitine was high in fibroblasts (which can happen in primary SCAD and MCAD, disorders of beta ox), but they used various ratios to rule out SCAD and MCAD and determine that the problem was secondary. Mutation analysis (when the mutation can be identified) can also determine which disorder is primary. As this abstract notes, traditionally, beta ox and the electron transport chain have been viewed as independent metabolic cycles. More recently it has become clear that a defect in one can cause derangements in the other, and do so fairly frequently. There are also cases where a primary defect in beta ox have caused a secondary problem in ETC, so the interaction can go both ways. This case also offers some interesting comments on the difficulties of managing the complication of a secondary defect. Barbara ----------------------------------- J Inherit Metab Dis. 2003;26(7):659-70. Respiratory complex II defect in siblings associated with a symptomatic secondary block in fatty acid oxidation. Gargus JJ, Boyle K, Bocian M, Roe DS, Vianey-Saban C, Roe CR. Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA 92697-4034, USA. jjgargus@u... The mitochondrial oxidative phosphorylation and fatty acid oxidation pathways have traditionally been considered independent major sources of cellular energy production; however, case reports of patients with specific enzymatic defects in either pathway have suggested the potential for a complex interference between the two. This study documents a new site of interference between the two pathways, a site in respiratory complex II capable of producing clinical signs of a block in fatty acid oxidation and reduced in vitro activity of acyl-CoA dehydrogenases. The initial patient, and later her newborn sibling, had mildly dysmorphic features, lactic acidosis and a defect in mitochondrial respiratory complex II associated with many biochemical features of a block in fatty acid oxidation. Results of in vitro probing of intact fibroblasts from both patients with methyl[2H3]palmitate and L-carnitine revealed greatly increased [2H3]butyrylcarnitine; however, the ratio of dehydrogenase activity with butyryl-CoA with anti-MCAD inactivating antibody (used to reveal SCAD-specific activity) to that with octanoyl-CoA was normal, excluding a selective SCAD or MCAD deficiency. Respiratory complex II was defective in both patients, with an absent thenoyltrifluoroacetone-sensitive succinate Q reductase activity that was partially restored by supplementation with duroquinone. Although secondary, the block in fatty acid oxidation was a major management problem since attempts to provide essential fatty acids precipitated acidotic decompensations. This study reinforces the need to pursue broadly the primary genetic defect within these two pathways, making full use of increasingly available functional and molecular diagnostic tools. > Malisa > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > My understanding is that secondary defects are probably > present from the start due to biochemical " domino effects. " > > > > > I missed this sentence....maybe that's why they say FOD's are secondary to > mito? If something isn't working in the electron transport chain then maybe it > backs up into the beta oxidation cycle??? More or less. When one cycle is out of balance, it may throw other cycles off kilter. Below I will paste the abstract I posted for about secondary beta ox problems in a child with a primary defect in the electron transport chain. In that case, the authors felt the biochemical evidence clearly indicated that the abnormalities in beta ox were secondary. Butyrylcarnitine was high in fibroblasts (which can happen in primary SCAD and MCAD, disorders of beta ox), but they used various ratios to rule out SCAD and MCAD and determine that the problem was secondary. Mutation analysis (when the mutation can be identified) can also determine which disorder is primary. As this abstract notes, traditionally, beta ox and the electron transport chain have been viewed as independent metabolic cycles. More recently it has become clear that a defect in one can cause derangements in the other, and do so fairly frequently. There are also cases where a primary defect in beta ox have caused a secondary problem in ETC, so the interaction can go both ways. This case also offers some interesting comments on the difficulties of managing the complication of a secondary defect. Barbara ----------------------------------- J Inherit Metab Dis. 2003;26(7):659-70. Respiratory complex II defect in siblings associated with a symptomatic secondary block in fatty acid oxidation. Gargus JJ, Boyle K, Bocian M, Roe DS, Vianey-Saban C, Roe CR. Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA 92697-4034, USA. jjgargus@u... The mitochondrial oxidative phosphorylation and fatty acid oxidation pathways have traditionally been considered independent major sources of cellular energy production; however, case reports of patients with specific enzymatic defects in either pathway have suggested the potential for a complex interference between the two. This study documents a new site of interference between the two pathways, a site in respiratory complex II capable of producing clinical signs of a block in fatty acid oxidation and reduced in vitro activity of acyl-CoA dehydrogenases. The initial patient, and later her newborn sibling, had mildly dysmorphic features, lactic acidosis and a defect in mitochondrial respiratory complex II associated with many biochemical features of a block in fatty acid oxidation. Results of in vitro probing of intact fibroblasts from both patients with methyl[2H3]palmitate and L-carnitine revealed greatly increased [2H3]butyrylcarnitine; however, the ratio of dehydrogenase activity with butyryl-CoA with anti-MCAD inactivating antibody (used to reveal SCAD-specific activity) to that with octanoyl-CoA was normal, excluding a selective SCAD or MCAD deficiency. Respiratory complex II was defective in both patients, with an absent thenoyltrifluoroacetone-sensitive succinate Q reductase activity that was partially restored by supplementation with duroquinone. Although secondary, the block in fatty acid oxidation was a major management problem since attempts to provide essential fatty acids precipitated acidotic decompensations. This study reinforces the need to pursue broadly the primary genetic defect within these two pathways, making full use of increasingly available functional and molecular diagnostic tools. > Malisa > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > My understanding is that secondary defects are probably > present from the start due to biochemical " domino effects. " > > > > > I missed this sentence....maybe that's why they say FOD's are secondary to > mito? If something isn't working in the electron transport chain then maybe it > backs up into the beta oxidation cycle??? More or less. When one cycle is out of balance, it may throw other cycles off kilter. Below I will paste the abstract I posted for about secondary beta ox problems in a child with a primary defect in the electron transport chain. In that case, the authors felt the biochemical evidence clearly indicated that the abnormalities in beta ox were secondary. Butyrylcarnitine was high in fibroblasts (which can happen in primary SCAD and MCAD, disorders of beta ox), but they used various ratios to rule out SCAD and MCAD and determine that the problem was secondary. Mutation analysis (when the mutation can be identified) can also determine which disorder is primary. As this abstract notes, traditionally, beta ox and the electron transport chain have been viewed as independent metabolic cycles. More recently it has become clear that a defect in one can cause derangements in the other, and do so fairly frequently. There are also cases where a primary defect in beta ox have caused a secondary problem in ETC, so the interaction can go both ways. This case also offers some interesting comments on the difficulties of managing the complication of a secondary defect. Barbara ----------------------------------- J Inherit Metab Dis. 2003;26(7):659-70. Respiratory complex II defect in siblings associated with a symptomatic secondary block in fatty acid oxidation. Gargus JJ, Boyle K, Bocian M, Roe DS, Vianey-Saban C, Roe CR. Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA 92697-4034, USA. jjgargus@u... The mitochondrial oxidative phosphorylation and fatty acid oxidation pathways have traditionally been considered independent major sources of cellular energy production; however, case reports of patients with specific enzymatic defects in either pathway have suggested the potential for a complex interference between the two. This study documents a new site of interference between the two pathways, a site in respiratory complex II capable of producing clinical signs of a block in fatty acid oxidation and reduced in vitro activity of acyl-CoA dehydrogenases. The initial patient, and later her newborn sibling, had mildly dysmorphic features, lactic acidosis and a defect in mitochondrial respiratory complex II associated with many biochemical features of a block in fatty acid oxidation. Results of in vitro probing of intact fibroblasts from both patients with methyl[2H3]palmitate and L-carnitine revealed greatly increased [2H3]butyrylcarnitine; however, the ratio of dehydrogenase activity with butyryl-CoA with anti-MCAD inactivating antibody (used to reveal SCAD-specific activity) to that with octanoyl-CoA was normal, excluding a selective SCAD or MCAD deficiency. Respiratory complex II was defective in both patients, with an absent thenoyltrifluoroacetone-sensitive succinate Q reductase activity that was partially restored by supplementation with duroquinone. Although secondary, the block in fatty acid oxidation was a major management problem since attempts to provide essential fatty acids precipitated acidotic decompensations. This study reinforces the need to pursue broadly the primary genetic defect within these two pathways, making full use of increasingly available functional and molecular diagnostic tools. > Malisa > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Malisa and Barbara, Once again, thank you both for posting such relevant and interesting source material. In your opinions, do you think that the presence of lipomas in mito might indicate a problem with fatty acid assimilation, too? Thank you! S. PA Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Malisa and Barbara, Once again, thank you both for posting such relevant and interesting source material. In your opinions, do you think that the presence of lipomas in mito might indicate a problem with fatty acid assimilation, too? Thank you! S. PA Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 I thought you saw Dr. Korson! It's great that you have such a knowledgable expert to help sort out your case. As for my beta ox defect, we know I have a primary CPT deficiency because I carry the R503C mutation in the CPT2 gene. But I also have a global mitochondrial defect that reduces all mitochondrial proteins. In muscle and fibroblasts, they have measured at least 16 different enzymes involved in beta ox (short, medium and long- chain), and they are all deficient. In muscle they measured respiratory chain enzymes and all were deficient. Given the fact that every mito enzyme they measure is deficient in both fibroblasts and muscle, and that non-mito enzymes are normal, the assumption is that all mito enzymes are deficient, even the ones we haven't measured. Underlying cause is thought to be a defect in mitochondrial transport, most likely one of the heat shock proteins. HSPs carry mito proteins in and out of the mitochondria, so if they are in short supply, then no mito protein can get in and out of the mitochondria in adequate amounts. The researchers who have worked on my case sent my fibroblasts to Denmark to the best heat shock protein team in the world, and they did what mutation screening they could for HSPs at the time, but did not find a mutation. Very few HSP mutations have been identified yet, so that was a long shot. Both the beta ox defect and the transport defect are primary, due to a nDNA mutation (one identified, one not). The part that gets so complicated is that the two defects overlap, in that half of the CPT deficiency comes from the global defect. The other half comes from the R503C mutation. Dr. Vladutiu has quite a time getting my other docs to understand how the two defects interact. This is probably more than you wanted to know, but I haven't figured out a way to explain it in fewer words....I think it was Mark Twain who once said he wrote a long letter to a friend because he didn't have time to write a short one. That's my problem too! Barbara > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > Dr. Korson said that complex I defects are often > associated with fatty acid oxidation impairment. He says the > approach to management may not change much if the FAO is confirmed, > but it might help point toward changes in vitamin or cofactor > therapy. > > > > > Hi Barbara, > Thank you so much for all your info! I agree that you have a wealth to share > with others. > Thanks for telling me about the chat transcript...Dr Korson is the mito doc > that I am seeing on Thursday so I am sure he will have things to add. > > Did they actually identify the type of FOD that you have? From what I > understand, sometimes they just know there is something abnormal going on in the > beta oxidation cycle but can't always identify the actual genetic name of > it....I guess it's similar to mito in that way! > > And....does anyone know how they figure out if the FOD is primary or > secondary? I almost always hear it is secondary, but don't really understand how > they figure that out. > Thanks again for your help! > Malisa > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 I thought you saw Dr. Korson! It's great that you have such a knowledgable expert to help sort out your case. As for my beta ox defect, we know I have a primary CPT deficiency because I carry the R503C mutation in the CPT2 gene. But I also have a global mitochondrial defect that reduces all mitochondrial proteins. In muscle and fibroblasts, they have measured at least 16 different enzymes involved in beta ox (short, medium and long- chain), and they are all deficient. In muscle they measured respiratory chain enzymes and all were deficient. Given the fact that every mito enzyme they measure is deficient in both fibroblasts and muscle, and that non-mito enzymes are normal, the assumption is that all mito enzymes are deficient, even the ones we haven't measured. Underlying cause is thought to be a defect in mitochondrial transport, most likely one of the heat shock proteins. HSPs carry mito proteins in and out of the mitochondria, so if they are in short supply, then no mito protein can get in and out of the mitochondria in adequate amounts. The researchers who have worked on my case sent my fibroblasts to Denmark to the best heat shock protein team in the world, and they did what mutation screening they could for HSPs at the time, but did not find a mutation. Very few HSP mutations have been identified yet, so that was a long shot. Both the beta ox defect and the transport defect are primary, due to a nDNA mutation (one identified, one not). The part that gets so complicated is that the two defects overlap, in that half of the CPT deficiency comes from the global defect. The other half comes from the R503C mutation. Dr. Vladutiu has quite a time getting my other docs to understand how the two defects interact. This is probably more than you wanted to know, but I haven't figured out a way to explain it in fewer words....I think it was Mark Twain who once said he wrote a long letter to a friend because he didn't have time to write a short one. That's my problem too! Barbara > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > Dr. Korson said that complex I defects are often > associated with fatty acid oxidation impairment. He says the > approach to management may not change much if the FAO is confirmed, > but it might help point toward changes in vitamin or cofactor > therapy. > > > > > Hi Barbara, > Thank you so much for all your info! I agree that you have a wealth to share > with others. > Thanks for telling me about the chat transcript...Dr Korson is the mito doc > that I am seeing on Thursday so I am sure he will have things to add. > > Did they actually identify the type of FOD that you have? From what I > understand, sometimes they just know there is something abnormal going on in the > beta oxidation cycle but can't always identify the actual genetic name of > it....I guess it's similar to mito in that way! > > And....does anyone know how they figure out if the FOD is primary or > secondary? I almost always hear it is secondary, but don't really understand how > they figure that out. > Thanks again for your help! > Malisa > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 I thought you saw Dr. Korson! It's great that you have such a knowledgable expert to help sort out your case. As for my beta ox defect, we know I have a primary CPT deficiency because I carry the R503C mutation in the CPT2 gene. But I also have a global mitochondrial defect that reduces all mitochondrial proteins. In muscle and fibroblasts, they have measured at least 16 different enzymes involved in beta ox (short, medium and long- chain), and they are all deficient. In muscle they measured respiratory chain enzymes and all were deficient. Given the fact that every mito enzyme they measure is deficient in both fibroblasts and muscle, and that non-mito enzymes are normal, the assumption is that all mito enzymes are deficient, even the ones we haven't measured. Underlying cause is thought to be a defect in mitochondrial transport, most likely one of the heat shock proteins. HSPs carry mito proteins in and out of the mitochondria, so if they are in short supply, then no mito protein can get in and out of the mitochondria in adequate amounts. The researchers who have worked on my case sent my fibroblasts to Denmark to the best heat shock protein team in the world, and they did what mutation screening they could for HSPs at the time, but did not find a mutation. Very few HSP mutations have been identified yet, so that was a long shot. Both the beta ox defect and the transport defect are primary, due to a nDNA mutation (one identified, one not). The part that gets so complicated is that the two defects overlap, in that half of the CPT deficiency comes from the global defect. The other half comes from the R503C mutation. Dr. Vladutiu has quite a time getting my other docs to understand how the two defects interact. This is probably more than you wanted to know, but I haven't figured out a way to explain it in fewer words....I think it was Mark Twain who once said he wrote a long letter to a friend because he didn't have time to write a short one. That's my problem too! Barbara > > In a message dated 9/17/2004 6:04:36 PM Eastern Standard Time, > wheatchild@n... writes: > > Dr. Korson said that complex I defects are often > associated with fatty acid oxidation impairment. He says the > approach to management may not change much if the FAO is confirmed, > but it might help point toward changes in vitamin or cofactor > therapy. > > > > > Hi Barbara, > Thank you so much for all your info! I agree that you have a wealth to share > with others. > Thanks for telling me about the chat transcript...Dr Korson is the mito doc > that I am seeing on Thursday so I am sure he will have things to add. > > Did they actually identify the type of FOD that you have? From what I > understand, sometimes they just know there is something abnormal going on in the > beta oxidation cycle but can't always identify the actual genetic name of > it....I guess it's similar to mito in that way! > > And....does anyone know how they figure out if the FOD is primary or > secondary? I almost always hear it is secondary, but don't really understand how > they figure that out. > Thanks again for your help! > Malisa > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Oh boy, I don't know enough about the etiology of lipomas to answer that. You would probably need more evidence of disturbed beta ox, but that is only a guess. I don't know what relationship lipomas have to cellular metabolism. Barbara > Dear Malisa and Barbara, > Once again, thank you both for posting such relevant and interesting > source material. > In your opinions, do you think that the presence of lipomas in mito > might indicate a problem with fatty acid assimilation, too? > Thank you! > S. > PA > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Oh boy, I don't know enough about the etiology of lipomas to answer that. You would probably need more evidence of disturbed beta ox, but that is only a guess. I don't know what relationship lipomas have to cellular metabolism. Barbara > Dear Malisa and Barbara, > Once again, thank you both for posting such relevant and interesting > source material. > In your opinions, do you think that the presence of lipomas in mito > might indicate a problem with fatty acid assimilation, too? > Thank you! > S. > PA > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Oh boy, I don't know enough about the etiology of lipomas to answer that. You would probably need more evidence of disturbed beta ox, but that is only a guess. I don't know what relationship lipomas have to cellular metabolism. Barbara > Dear Malisa and Barbara, > Once again, thank you both for posting such relevant and interesting > source material. > In your opinions, do you think that the presence of lipomas in mito > might indicate a problem with fatty acid assimilation, too? > Thank you! > S. > PA > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Barbara, Thanks for your response. Wish we all knew more about the causality of the myriad " things " we are all being hit with! But science marches on, and I am positive that many answers will evolve. I have great hope for those in their 20's and below. Take care. S. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Barbara, Thanks for your response. Wish we all knew more about the causality of the myriad " things " we are all being hit with! But science marches on, and I am positive that many answers will evolve. I have great hope for those in their 20's and below. Take care. S. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Barbara, Thanks for your response. Wish we all knew more about the causality of the myriad " things " we are all being hit with! But science marches on, and I am positive that many answers will evolve. I have great hope for those in their 20's and below. Take care. S. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 18, 2004 Report Share Posted September 18, 2004 Dear Barbara, Please excuse my ignorance, but the " heat shock proteins " you mentioned gave me pause. Do they have anything at all to do with how we handle heat and dehydration? When I told my neuro last week of the episodes I've had of scary heat exhaustion, and of Dr. Cohen's belief that chronic headaches in mito are caused by dehydration from intracranial hypotension, she said that I have to be one of those people you always see in NYC carrying around their water bottles. We both got a laugh when she said that some of the bottles look like they are little baby bottles. We both mocked the Hollywood types you see, always sucking on their bottles.... Thank you very much! S. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.